Status: open

COBRRA STUDY

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban

 

Why are we doing this study?

This smaller study compares Apixaban and Rivaroxaban, two types of oral blood thinners, for the treatment of blood clots. The main objective is to determine if a larger scale study is worthwhile to undertake in the future.

 

Who is eligible?

If you are newly diagnosed (less than 2 weeks) with a deep vein thrombosis (DVT) or a pulmonary embolism (PE).

 

What is the study treatment plan?

Half the patients will be selected by chance to receive either:  Apixaban 10mg twice daily or: Rivaroxaban 15mg tablets twice daily for 3 weeks then 20mg tablets once daily (either of these therapies is usual treatment and likely to be prescribed by your doctor)

 

What is involved if I participate in the study?

There are 2 study visits, participants will be followed up at:

  • 2 weeks
  • 3 months

 

COBRRA Study Coordinator:

Elena Shulikovsky
TEL: 514-340-8222 ext. 23703